VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Duck Hepatitis Virus Vaccine rDEV-US7/8-P13C
Vaccine Information
  • Vaccine Name: Duck Hepatitis Virus Vaccine rDEV-US7/8-P13C
  • Target Pathogen: Duck hepatitis virus 1
  • Target Disease: Duck virus hepatitis (DVH)
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: Duck
  • Antigen: (Yang et al., 2021) P1, 3C
  • Preparation: (Yang et al., 2021) The P1-P2A-3C cassette was inserted into the gene junction between US7 and US8 in the DEV vaccine strain genome. For transfection, we used the modified fosmid C343-US7/8-P13C, which replaced the parental fosmid C343. After being blindly passaged once in CEFs, DEV-typical plaques appeared in the CEFs transfected with the DNA combinations. Electron microscopy confirmed the successful rescue of the recombinant viruses. Insertion of the P1-P2A-3C cassette at the proper site was confirmed by PCR and sequencing, using a forward primer specific to the P1 gene and a reverse primer matching the US8 sequence. The recombinant DEVs was designated rDEV-US7/8-P13C, with the P1 and 3C genes inserted between US7 and US8, in the DEV genome.
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: A bivalent duck hepatitis virus recombinant vector vaccine that is made of a P1-P2a-33 cassette inserted between US7 and US8 of the viral genome (Yang et al., 2021).
Host Response

Ducks Response

  • Vaccination Protocol: (Yang et al., 2021) Groups of 20 ducks were inoculated with 1000 ELD50 of the recombinant viruses to evaluate the antibody responses against DHAV-3 and DEV induced by the recombinant DEVs.
  • Challenge Protocol: (Yang et al., 2021)All the animal experiments were performed using SPF ducks housed in filtered-air, negative-pressure isolation units. The ducks were given free access to food and water. To evaluate the protective efficacy of the recombinant viruses against challenge by the virulent DHAV-3 and DEV, each group of 20 ducks was inoculated subcutaneously with 1,000 times the 50% egg lethal dose (1000 ELD50) of the rescued viruses at 1 day of age. At 7 days post-vaccination, 10 ducks in each group were intramuscularly challenged with 100 ELD50 of the virulent DHAV-3 A3 strain, and the remaining 10 ducks were intramuscularly challenged with 1,000 minimum lethal doses of the virulent DEV CSC strain. Ten unvaccinated and unchallenged ducks were used as the healthy controls. The ducks were examined for clinical signs and mortality for 2 weeks after the challenge. The dead and surviving ducks were observed for gross lesions in the liver, spleen, kidneys, esophagus, intestine, thymus, and bursa.
  • Description: (Yang et al., 2021) The ducks were inoculated with the recombinant viruses at 1 day of age and challenged with the virulent DHAV-3 A3 strain 7 days post-inoculation for protective efficacy evaluation. These ducks did not show any clinical signs in response to vaccination before the challenge. The ducks in the rDEV-US7/8-P13C vaccination group were completely protected from lethal DHAV-3 challenge, showing no clinical signs of disease and no visible lesions in the liver, spleen, or other organs during the 2-week observation period. However, all ducks in the challenge control group showed severe clinical signs from 2 days post-challenge, including depression, lethargy, and anorexia; all these ducks died from the DHAV-3 challenge within 3 days. As expected, the ducks in the healthy control group did not show any clinical signs during the experiment. These results indicate that rDEV-US7/8-P13C induced 100% protection against lethal DHAV-3 challenge in ducks.
References